Evidence map›Paper›PMID 36015109›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Identification of a Dual Inhibitor of Secreted Phospholipase A

Maria A Theodoropoulou, Giorgos S Koutoulogenis, Linlin Zhang, Ifigeneia Akrani, Emmanuel Mikros, Rolf Hilgenfeld, George Kokotos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Maria A TheodoropoulouDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece.ORCID 0000-0002-6552-5217
Giorgos S KoutoulogenisDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece.
Linlin ZhangInstitute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany.
Ifigeneia AkraniDepartment of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece.
Emmanuel MikrosDepartment of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece.ORCID 0000-0002-5984-5169
Rolf HilgenfeldInstitute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany.ORCID 0000-0001-8850-2977
George KokotosDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece.ORCID 0000-0003-3753-7082
National and Kapodistrian University of Athens · GRGerman Center for Infection Research · DEUniversity of Lübeck · DE

Funding

European Regional Development Fund (ERDF) and Greek national fund 5134646European Union 10100362Hellenic Foundation for Research and Innovation 18603Stavros Niarchos Foundation
6 · The paper itself

Abstract

The development of novel agents to combat COVID-19 is of high importance. SARS-CoV-2 main protease (M

Indexed as

2-oxoamidesCOVID-19inhibitorsmain proteasephospholipase A2SARS-CoV-2

Identifiers

PMID36015109
PMCPMC9414318
OpenAlexW4289731679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.